Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.224.70.160
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Genetic and Congenital
Journal Scan
Trending Topics

Ganaxolone reduces frequency of CDKL5 deficiency disorder-associated seizures

Posted on

Patients with CDKL5 deficiency disorder (CDD) had less frequent CDD-associated seizures when treated with an investigational neuroactive steroid, Ganaxolone, compared with placebo, according to the results of a phase 3 trial.

In the double-blind phase of this randomized, placebo-controlled, 101 patients between the ages of 2-21 years with a pathogenic or probably pathogenic CDKL5 variant and ≥16 major motor seizures per 28 days in each 4-week period of an 8-week historical period were randomly assigned to receive either ganaxolone (n = 50) or placebo (n = 51) for 17 weeks.

The primary endpoint, which was percentage change in median 28-day major motor seizure frequency from the baseline period to the 17-week double-blind phase was analyzed in a population of 100 patients due to 1 patient in the ganaxolone group not having seizure frequency recorded at baseline.

-Advertisement-
-Advertisement-

In the ganaxolone group and the placebo group, the median percentage change in 28-day major motor seizure frequency was 30.7% (IQR -49.5 to -1.9) and -6.9% (-24.1 to 39.7), respectively. The Hodges-Lehmann estimate of median difference in responses to ganaxolone versus placebo was -27.1% (95% CI -47.9 to – 9.6).

Treatment-emergent adverse events were reported in 86% of 50 patients in the ganaxolone group and in 88% of 51 patients in the placebo group. At least 10% of patients in the ganaxolone group experienced somnolence, pyrexia, and upper respiratory tract infections.

Six patients and 5 patients experienced serious adverse events in the ganaxolone group and placebo group, respectively. In the ganaxolone group, 2 (4%) patients discontinued the trial; in the placebo group, 4 (8%) patients discontinued. There were no deaths in the double-blind phase.

Reference
Knight EMP, Amin S, Bahi-Buisson N, et al; Marigold Trial Group. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21(5):417-427. doi: 10.1016/S1474-4422(22)00077-1. PMID: 35429480.

 

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-